Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts.
about
Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicineRegulatory pathways for ATP-binding cassette transport proteins in kidney proximal tubulesPharmGKB summary: cyclosporine and tacrolimus pathwaysDonor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up.Cyclosporine: a review.Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium.Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation.Subclinical inflammation and chronic renal allograft injury in a randomized trial on steroid avoidance in pediatric kidney transplantationTop Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.Donor ABCB1 variant associates with increased risk for kidney allograft failure.Exploring genetic and non-genetic risk factors for delayed graft function, acute and subclinical rejection in renal transplant recipients.Influence of tacrolimus metabolism rate on renal function after solid organ transplantation.Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.Assessment of kidney organ quality and prediction of outcome at time of transplantation.The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation.New insights on molecular mechanisms of renal aging.Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.Genes and beans: pharmacogenomics of renal transplant.Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence.Pharmacogenetics in solid organ transplantation: genes involved in mechanism of action and pharmacokinetics of immunosuppressive drugs.Practicability of pharmacogenetics in transplantation medicine.The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.Calcineurin inhibitors and hypertension: a role for pharmacogenetics?Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients.Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes.Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine A/azathioprine or cyclosporine A/mycophenolate mofetil bitherapy to cyclosporine A monotherapy: a 10-year postrandomization follow-up study.Pharmacogenetics of tacrolimus: ready for clinical translation?Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure.CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation.Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.Loaded, locked, drawn: kSORT validated for patient samples.Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis.The time dependency of renal allograft histology.Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients.The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients.Tacrolimus-induced hypertension and nephrotoxicity in Fawn-Hooded rats are attenuated by dual inhibition of renin-angiotensin system.
P2860
Q28082746-3DABB7ED-19FC-406E-A95A-FC6F94148A66Q28390004-D70655D5-F81E-493E-A274-C8AED40983F9Q33989902-BAC0F8B0-6C4B-4084-905A-C8C6122EFF57Q34475012-1EF628A5-1594-4C6D-B8EB-46ED88B8CF67Q35675934-2BF7FBDA-1BC9-4B43-9F19-75880991AD49Q35823308-86B6A0F4-8DF7-4408-86FE-31BE8801712AQ36016669-D0CA463B-A60F-47A9-8B8F-21B5D570A8A9Q36281955-EB711D25-6C10-466F-B5FD-D2DF8698A294Q36285918-4A5D91E8-AC65-4ECB-AEBF-E64508313175Q36352165-BAF40A71-7BB6-4482-AC6E-BADA82B08BC0Q37030707-E060540F-05DC-40A3-95FE-71B98101C1D3Q37662992-DB8EB8AC-F985-4FA2-86F4-29B84A91D5B7Q37678060-1A14DCD6-4DD8-49B6-ABF9-12A60CF41845Q37832966-E27A5F26-B361-4D47-B9C6-38D484B71CD4Q37857285-7138673B-8CB0-479D-86F5-2C0CC4253957Q38033716-FF5373F4-6C22-45BB-9DE1-7F7D75D55AF7Q38063426-E67009EC-8E91-4976-923F-27BD98E9C677Q38104742-5F76AAEA-99FE-4AC8-95BF-DBE3CCB0D79EQ38116657-F2F6FF2C-8AB4-43DC-92A5-7FB54676472CQ38120290-69ECE34F-3DFD-4FCE-A465-07181578211FQ38133294-23BE0E84-5544-4206-B5E8-0F60B8B955CBQ38163945-3122851F-EB17-4F12-BF9E-6701562097FCQ38241677-CFFBA489-3434-4ED4-AFE6-D9D72B24338AQ38414396-7A5FD546-8E12-4AF6-9157-6E15BE2013EAQ38435024-253BAE85-CAC0-4012-90A0-846752148B5AQ38748975-864EC1B8-9BA1-48D1-B94E-4A698B9E7F62Q38787174-95AC092D-EC18-4BE3-8B79-D4E65826AAF4Q39712114-D6347194-3186-433E-B3EF-D25E0AF5665FQ41001229-DD08626A-B0E1-490F-AA01-9C458468AF7AQ42143648-B0EC0894-1DEC-4B39-B9C8-D78244BC348AQ43059203-2B8E1571-A8F5-4290-A034-5621C485B7D8Q44276263-024A3BEF-2C18-497C-9538-D9EBF11BB388Q44805468-D0CBDABA-C518-4BF6-9AE7-45E4B2D1C06CQ45279289-EFA252B4-78AA-43EC-A467-9781C6891FF2Q46857010-F34B9A01-5CF4-40FC-8F7C-0E96F5CD025EQ47799865-C9DE3612-8515-46E1-82AD-EC8DCE626FD6Q48162490-6F2D16AA-D1C8-4D9E-AECA-3F53F40A5F30Q49792894-2D6A6E61-5CE0-4DD7-8A82-57775B96AE39Q50451919-21C1E38B-898D-4C75-97A9-397E9DA321E0Q53860769-7AC1D006-4AB8-4306-A591-583058C9BDBE
P2860
Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Donor age and renal P-glycopro ...... al damage in renal allografts.
@ast
Donor age and renal P-glycopro ...... al damage in renal allografts.
@en
Donor age and renal P-glycopro ...... al damage in renal allografts.
@nl
type
label
Donor age and renal P-glycopro ...... al damage in renal allografts.
@ast
Donor age and renal P-glycopro ...... al damage in renal allografts.
@en
Donor age and renal P-glycopro ...... al damage in renal allografts.
@nl
prefLabel
Donor age and renal P-glycopro ...... al damage in renal allografts.
@ast
Donor age and renal P-glycopro ...... al damage in renal allografts.
@en
Donor age and renal P-glycopro ...... al damage in renal allografts.
@nl
P2093
P2860
P356
P1476
Donor age and renal P-glycopro ...... al damage in renal allografts.
@en
P2093
Boudewijn Van Damme
Dirk R J Kuypers
Evelyne Lerut
Hylke de Jonge
Yves Vanrenterghem
P2860
P304
P356
10.1681/ASN.2009020192
P577
2009-09-17T00:00:00Z